Monday, August 8, 2022 Daily Archives

OriCell plans CAR-T plant after $120m funding boost

by

OriCell Therapeutics has closed a $120 million Series B financing set to support its cell therapy and bispecific immunotherapy pipeline. The Shanghai, China-based company also plans to build a clinical/commercial manufacturing plant, though the location or further details are yet to be revealed. OriCell has two chimeri antigen receptor (CAR) T candidates that are close to clinical stage, one for advanced liver cancer and the other for multiple myeloma. It is also developing a PD-L/4-1BB bispecific antibody that it partnered…

August 8, 2022

Charles River looks to CGT growth to offset ‘bumpiness’ in CDMO biz

by

Stabilizing acquired CDMO businesses is proving “elusive and expensive” say analysts, but Charles River is confident cell and gene therapies entering the clinic will be the foundation of future growth. For the second quarter 2022, Charles River Laboratories reported revenue from its manufacturing segment of $195 million, down 1.5% on the same quarter last year. Furthermore, the company is reducing its 2022 financial guidance from revenue growth of 13.5-15.5% to 9-11% in part due to “headwinds associated with the CDMO…

August 8, 2022

Plasmid production a plus for Polyplus

by

Polyplus has added transgene plasmid engineering services for viral vector manufacturing, which it says allows customers to get their gene therapies to market quicker. The French biotech claims that since acquiring DNA design and production services firm e-Zyvec in February, it has focused on providing more advanced levels of solutions to support its client base. By using e-Zyvec’s technology “the plasmids are assembled de novo, from a library of DNA bricks, removing the use of standard plasmid backbones that contain…

August 8, 2022